Hantaan virus vaccine - Janssen Vaccines
Alternative Names: Hantaan virus vaccine; Hantavax; ROK 84-105Latest Information Update: 28 Feb 2019
Price :
$50 *
At a glance
- Originator GreenCross Vaccine
- Developer Janssen Vaccines
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hantaan virus infections
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for clinical-Phase-Unknown development in Hantaan-virus-infections in Yugoslavia (Injection, Injection)
- 23 Sep 2015 Green Cross plans a phase III trial in Hantaan virus infections (Prevention) in South Korea (IM or SC) (NCT02553837)
- 31 Oct 2002 Rhein Biotech has been acquired by Berna Biotech